Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

SR9009 (Stenabolic)

REV-ERB agonist (NOT a SARM)

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not FDA approved; tool compound only
WADA
Prohibited at all times (S4.5 Metabolic Modulators)

Reference only. Not medical advice.

What can go wrong

There are no human safety data. The dominant practical issue is that oral SR9009 is unlikely to be biologically active given near-zero oral bioavailability, so consumers pay for an ineffective oral form. Products are unregulated and often mislabeled or bundled with SARMs. Prohibited in WADA sport.

This is something to take to a clinician. The Atlas can tell you what is known about sr9009 (stenabolic) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

SR9009 (Stenabolic) is a REV-ERB agonist developed by Thomas Burris's lab at Scripps as a research tool compound, not an androgen modulator, so it is not a SARM. In mice it increased mitochondrial content and endurance, earning 'exercise in a pill' hype. Critically, the Burris lab's own work indicates SR9009 has essentially zero oral bioavailability, meaning the pills widely sold online are unlikely to deliver a biologically active oral dose.

'Exercise in a pill', except its oral bioavailability is essentially zero.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Marketed (illegally) for endurance and fat loss

How it is supposed to work

SR9009 activates REV-ERB (REV-ERBalpha), a nuclear receptor and circadian-clock component that regulates metabolism and mitochondrial function. In mice, activation increased skeletal-muscle mitochondrial content and running capacity. This is a circadian/metabolic mechanism with no relationship to androgen receptors.

The oral-dosing problem

The mouse endurance results were obtained largely with injected drug. The Burris lab reported that SR9009 has very poor (near-zero) oral bioavailability, so an oral capsule is unlikely to reach active systemic levels. The compound is best understood as an early tool that opened up REV-ERB biology, not a finished, orally active drug, which undercuts the entire 'exercise pill' consumer proposition.

Safety in detail

SR9009 is an unapproved research tool compound with no human trials and essentially no oral bioavailability. It is not a SARM. Consumer oral products lack a plausible basis for efficacy and have unknown safety.

What it does to fertility

No androgenic/HPTA mechanism; not a testosterone-suppressing SARM. Human reproductive effects are unstudied.

What has to be monitored

The bloodwork this needs, and the reason it belongs with a clinician rather than a website.

  • No validated human use; monitoring parameters are undefined
  • General avoidance is the appropriate stance

What people get wrong

  • Often saidSR9009 is a SARM

    ActuallyIt is a REV-ERB agonist, a circadian/metabolic mechanism with no androgen activity.

  • Often saidAn oral Stenabolic capsule gives you the mouse endurance effect

    ActuallyThe mouse effects used injected drug; oral SR9009 has essentially zero bioavailability, so the pill form is unlikely to work.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

How we got here

SR9009 was created in the lab of Thomas Burris at Scripps Research as a synthetic REV-ERB agonist to probe circadian and metabolic biology. High-profile mouse endurance findings (2012-2013) generated 'exercise in a pill' headlines, but the compound was never drug-like, its poor oral bioavailability is documented by the originating lab. It nonetheless entered the gray market as Stenabolic, misclassified as a SARM.

  1. 2012Solt et al. describe REV-ERB agonists in Nature
  2. 2013Woldt et al. report endurance effects in mice
  3. 2010sSold as 'Stenabolic,' marketed as a SARM/'exercise pill'

At a glance

Class
REV-ERB agonist (NOT a SARM)
Originator
Thomas Burris lab, Scripps
Oral bioavailability
Essentially zero
Human trials
None

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about SR9009 (Stenabolic). A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Solt et al., REV-ERB agonists SR9009/SR9011 (Nature)2012

    REV-ERB activation altered circadian behavior and metabolism

  • Woldt et al., REV-ERBalpha and muscle mitochondrial function/exercise (Nat Med)2013

    SR9009 increased mitochondrial content and running capacity in mice